Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
409. lappuse
... system . A 1,500 - watt im- mersion heating element connected to a partial immersion , contact thermom- eter and an appropriate control relay . ( 3 ) Circulating system components . The circulating system consists of three different ...
... system . A 1,500 - watt im- mersion heating element connected to a partial immersion , contact thermom- eter and an appropriate control relay . ( 3 ) Circulating system components . The circulating system consists of three different ...
418. lappuse
... system operating at a wavelength of 254 nanometers ; ( 4 ) A suitable recorder of at least 25.4 centimeter deflection ; ( 5 ) A 30 - centimeter column having an inside diameter of 4.0 millimeters and packed with a suitable reverse phase ...
... system operating at a wavelength of 254 nanometers ; ( 4 ) A suitable recorder of at least 25.4 centimeter deflection ; ( 5 ) A 30 - centimeter column having an inside diameter of 4.0 millimeters and packed with a suitable reverse phase ...
419. lappuse
... system operating at a wavelength of 340 nanometers ; ( 4 ) A suitable recorder of at least 25.4 centimeter deflection ; ( 5 ) A suitable integrator ; ( 6 ) A column approximately 25 centi- meters in length having an inside di- ameter of ...
... system operating at a wavelength of 340 nanometers ; ( 4 ) A suitable recorder of at least 25.4 centimeter deflection ; ( 5 ) A suitable integrator ; ( 6 ) A column approximately 25 centi- meters in length having an inside di- ameter of ...
421. lappuse
... System suitability test . Equilibrate and condition the column by passage of about 10 to 15 void volumes of mobile phase followed by two or more rep- licate injections of 10 microliters each of the working standard solution . Allow an ...
... System suitability test . Equilibrate and condition the column by passage of about 10 to 15 void volumes of mobile phase followed by two or more rep- licate injections of 10 microliters each of the working standard solution . Allow an ...
423. lappuse
... system operating at a wavelength of 254 nanometers ; ( 4 ) A suitable recorder of at least 25.4 - centimeter deflection ; ( 5 ) A suitable integrator ; ( 6 ) A 25 - centimeter column having an inside diameter of 4.6 millimeters and ...
... system operating at a wavelength of 254 nanometers ; ( 4 ) A suitable recorder of at least 25.4 - centimeter deflection ; ( 5 ) A suitable integrator ; ( 6 ) A 25 - centimeter column having an inside diameter of 4.6 millimeters and ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning